



**Richard Moscicki, M.D.**

**Chief Medical Officer and Executive Vice President of Science and Regulatory Advocacy**

Richard (Rich) A. Moscicki (Mo-shis-ke), M.D., is the executive vice president of science and regulatory advocacy and the chief medical officer at the Pharmaceutical Research and Manufacturers of America (PhRMA).

Dr. Moscicki came to PhRMA in 2017 after serving as the deputy center director for science operations for the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) since 2013. While at FDA, Dr. Moscicki brought executive direction of Center operations and leadership in overseeing the development, implementation, and direction of CDER's programs. Previous positions include serving as chief medical officer at Genzyme Corporation from 1992 to 2011 where he was responsible for worldwide global regulatory and pharmacovigilance matters, as well as all aspects of clinical research and medical affairs for the company. He served and a senior vice president and head of clinical development at Sanofi-Genzyme from 2011-2013.

Dr. Moscicki received his medical degree from Northwestern University Medical School. He is board certified in internal medicine, diagnostic and laboratory immunology, and allergy and immunology. He completed his residency in Internal Medicine, followed by a fellowship at Massachusetts General Hospital (MGH) in clinical immunology and immunopathology. He remained on staff at MGH and on the faculty of Harvard Medical School from 1979 until 2013.



**Chris Hourigan**

**PhRMA JBEC Chair**

Having held roles that have spanned business quality, supply chain and manufacturing, marketing, sales, business development and general management, Hourigan has experience across the full value chain of pharmaceuticals. He currently serves as President of Janssen Pharmaceutical K.K., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, a role he has held since January 2016. Prior to this, Hourigan was Managing Director of Janssen Australia & New Zealand (ANZ), where he played a key role in supporting the local industry as a member of the Medicines Australia Board. He has also worked with the company in leadership roles in Vietnam, New Zealand and the U.S.